ReviewArchives of microbiology2026
Microbial and enzymatic biodegradation of aflatoxins and ochratoxins: mechanisms, applications, and emerging innovations.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Biodegradation of Aflatoxins by Four Novel Environmental Bacterial Isolates: A Comparative Genomic and Molecular Docking-Proof-of-Concept Study.Foods (Basel, Switzerland) · 2026Article
- Review
- Detoxification of aflatoxin MScientific reports · 2026Article
- Screening of Plant-Derived Lactic Acid Bacteria for Faba Bean Fermentation and Their Mycotoxin Removal Capacity.Microorganisms · 2026Article
- Biocontrol of Mycotoxin-Producing Fungi by Lactic Acid Bacteria.Foods (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aflatoxins and ochratoxins are highly potent mycotoxins primarily produced by Aspergillus and Penicillium species, contaminating various agricultural commodities, especially cereals, nuts, and animal feeds. Chronic exposure to these mycotoxins is associated with liver cancer, immunosuppression, and developmental disorders, posing significant risks to public health and socioeconomic stability in numerous developing countries. Detoxification of mycotoxins has traditionally depended on physical and chemical methods, which exhibit limitations such as partial efficacy, nutrient loss, changes in food quality, high energy requirements, and environmental issues. Biological detoxification has recently garnered significant attention as a sustainable, safe, and eco-friendly alternative. This method utilises microorganisms, including bacteria, yeast, and fungi, along with their enzymes and metabolites, to transform mycotoxins into less toxic or non-toxic compounds, while maintaining the nutritional and sensory quality of food and feed. This review systematically analyses the recent advancements in the understanding of the microbiological and enzymatic mechanisms of aflatoxin (AFB) and ochratoxin (OTA) degradation. It emphasises the function of essential enzymes such as aldehyde dehydrogenase, amidohydrolase, carboxypeptidases, laccases, manganese peroxidases and oxidases, transforming AFB1 and OTA into less toxic compounds like AFD1, AFQ1, L-β-phenylalanine and OTα. Industrial applications of these enzymes in feed and food processing are discussed. Contemporary challenges, including incomplete degradation, the formation of unknown by-products, and the variability of enzyme performance across different food matrices, are reviewed. The review proposes strategic approaches to enhance biological detoxification efficiency. These insights provide a framework for developing scalable, safe, and effective biotechnology solutions to mitigate mycotoxin contamination in the global food chain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.